Loading...
Market
What will be the outcome of the Phase II M-PACT trial for SLS-002 in treating PTSD by June 30, 2025?
2
Resolution / Starting Odds
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative effects • 25%
Trial results published by USAMMDA or Seelos Therapeutics
Story
Seelos Therapeutics ($SEEL) Signs Agreement with USAMMDA to Evaluate SLS-002 for PTSD, Stock Surges 115.8%
Sep 24, 2024, 12:38 PM
Seelos Therapeutics ($SEEL) has announced the signing of a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate its intranasal ketamine, SLS-002, for the treatment of PTSD. This agreement includes the inclusion of SLS-002 in the U.S. Department of Defense’s M-PACT trial, which will begin dosing in the fourth quarter of 2024. The Phase II trial will assess the safety, efficacy, and tolerability of SLS-002 in active-duty service members and veterans. Following this announcement, Seelos Therapeutics' stock surged by 115.8% in pre-market trading.
View original story
Similar markets
Study shows significant positive results • 25%
Study shows moderate positive results • 25%
Study shows no significant effect • 25%
Study shows negative results • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Effective for both PTSD and alcohol use disorder • 25%
Effective only for PTSD • 25%
Effective only for alcohol use disorder • 25%
Not effective for either condition • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Positive • 25%
Negative • 25%
Inconclusive • 25%
No major trial outcome • 25%
Approved without restrictions • 25%
Approved with restrictions • 25%
Rejected • 25%
Decision delayed • 25%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened condition • 25%
Significant positive results • 25%
Moderate positive results • 25%
No significant results • 25%
Negative results • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%